Prosecution Insights
Last updated: October 25, 2026
Application No. 18/832,143

Anticancer Compounds, Pharmaceutical Compositions, and Methods of Treating Cancers

Non-Final OA §102§Other
Filed
Jul 23, 2024
Priority
Feb 16, 2022 — provisional 63/310,601 +1 more
Examiner
RAO, SAVITHA M
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Miralogx LLC
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
5m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
724 granted / 1192 resolved
+0.7% vs TC avg
Strong +30% interview lift
Without
With
+29.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
40 currently pending
Career history
1227
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
17.7%
-22.3% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1192 resolved cases

Office Action

§102 §Other
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-13 are pending Claims 4-5 , 7-8 and 10-13 are withdrawn from examination as being drawn to a nonelected specie. Claims 1-3, 6 and 9 are under consideration in the instant office action. Election/Restrictions Applicant’s election without traverse of Group 1 (claims 1-9) and the following species in their response dated 7/27/2026 is acknowledged. Specie 1: Compound: Applicants elect the following compo9und (claim 3, 4th structure) PNG media_image1.png 274 427 media_image1.png Greyscale Examination of the claims are conducted to the extent they read on the elected species. Claims 4-5, 7-8 and 10-13 are withdrawn from examination as being drawn to a nonelected specie. Claims 1-3, 5 and 9 are under examination and the requirement for restriction is made final. Information Disclosure Statement The information disclosure statement (IDS) submitted on 07/23/2024 complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. Accordingly, it has been placed in the application file and the information therein has been considered as to the merits. See attached copy of the PTO-1449. Priority The present application claims priority under 35 U. S. C. ?119 to U.S. Provisional application 63/310601, filed February 16, 2022 . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-3, 5 and 9 are rejected under 35 U.S.C. 102 (a) (1) and under 35 U.S.C 102(a)(2) as being anticipated by Burnette et al. (US 2021/0177825, reference cited in IDS dated 07/23/2024) Instant claims are drawn to a compound of formula (I) with the following structure PNG media_image1.png 274 427 media_image1.png Greyscale . Burnette et al.discloses the instantly claimed compound as compound SG-102, (the second compound on page 53 (table 1 continued) as follows: PNG media_image2.png 261 337 media_image2.png Greyscale Therefore the composition disclosed by Burnette et al. fully anticipates instant claims 1-3, 6 and 9 Conclusion Claims 1-3, 6 and 9 are rejected. No claims are allowed Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAVITHA RAO whose telephone number is (571)270-5315. The examiner can normally be reached on Mon-Fri 7 am to 4 pm.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAVITHA M RAO/ Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Jul 23, 2024
Application Filed
Aug 13, 2026
Non-Final Rejection mailed — §102, §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758515
METHOD OF TREATING DIABETES AND RELATED METABOLIC DISEASE BY ACAT INHIBITION
5y 4m to grant Granted Oct 13, 2026
Patent 12758567
COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
3y 2m to grant Granted Oct 13, 2026
Patent 12758524
PROPHYLACTIC OR THERAPEUTIC DRUG FOR PARKINSON'S DISEASE
2y 9m to grant Granted Oct 13, 2026
Patent 12751941
STABLE PHARMACEUTICAL COMPOSITION
3y 7m to grant Granted Oct 06, 2026
Patent 12753166
SALT CONTAINING PIPERAZINE POLYCYCLIC DERIVATIVE, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
2y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
90%
With Interview (+29.7%)
2y 8m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1192 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month